Company intelligence / Profile preview

Akorn Pharmaceuticals

Lake Forest / Gurnee, Illinois, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Other

Overview

At its peak, Akorn was a vertically integrated specialty pharmaceutical company with a focus on generic and branded prescription drugs for human and animal health. It developed a broad portfolio in ophthalmology, anesthesia, antidotes, respiratory care, rheumatology/allergy, OTC consumer health products for dry eye/cough/cold/magnesium supplementation. The company ceased all operations in February 2023 after filing for Chapter 7 bankruptcy. No current clinical results or pipeline exist due to liquidation.

Therapeutic areas: RheumatologyOphthalmologyPulmonologyOther
Modalities: Small moleculeBiologicDevice
Industry: Biotech

Drug pipeline

1 asset

bimatoprost ophthalmic solution

Commercial

Indications: Ophthalmic conditions

Partnerships

Licensed/acquired products from Allergan Inc.ALZA Corp.Janssen Pharmaceutical

Beyond the preview

Go deeper on Akorn Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akorn Pharmaceuticals.

Explore the full profile